Long-Term Hormonal Therapy: Who Would Benefit? François Desgrandchamps  European Urology Supplements  Volume 9, Issue 8, Pages 695-700 (October 2010) DOI: 10.1016/j.eursup.2010.08.003 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 – Prostate cancer–related deaths with immediate versus delayed treatment in patients with advanced prostate cancer. Reproduced with permission from [4]. European Urology Supplements 2010 9, 695-700DOI: (10.1016/j.eursup.2010.08.003) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 – Baseline prostate-specific antigen (PSA) levels as a prognostic marker of mortality in (A) immediate and (B) deferred treatment. Reprinted from [6], Copyright (2008), with permission from Elsevier. European Urology Supplements 2010 9, 695-700DOI: (10.1016/j.eursup.2010.08.003) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 – Immediate versus deferred androgen-deprivation therapy (ADT) in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. CI=confidence interval. Reprinted from [7], Copyright (2006), with permission from Elsevier. European Urology Supplements 2010 9, 695-700DOI: (10.1016/j.eursup.2010.08.003) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 – Overall survival rates in patients with prostate cancer treated with either radiation therapy (RT) with hormonal therapy (HT) at relapse or with RT with adjuvant HT. Reprinted from [9], Copyright (2005), with permission from Elsevier. European Urology Supplements 2010 9, 695-700DOI: (10.1016/j.eursup.2010.08.003) Copyright © 2010 European Association of Urology Terms and Conditions